Accela Pharmaceuticals Private Limited
About Accela Pharmaceuticals Private Limited
Data last updated:
Accela Pharmaceuticals Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 05 July 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24232PN2010PTC136759.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹1.5 Lakh. It is led by directors Pragati Dinesh Bothara and Dinesh Keshari Chand Bothra.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at S No. 118 To 124 Plot No 98 National Soc Aundh, Pune, Maharashtra, India – 411021.
As per the financials filed for FY 2023, the company reported a revenue of ₹10 Lakh, a decline of 31% compared to the previous year. For the same year it recorded a net profit of ₹7.74 Lakh (net margin 77.4%) and EBITDA of ₹9.75 Lakh (EBITDA margin 97.5%).
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Accela Pharmaceuticals Private Limited's registered office is in Pune, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressS No. 118 To 124 Plot No 98 National Soc Aundh, Pune, Maharashtra, India – 411021
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Accela Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Accela Pharmaceuticals Private Limited
FY 2025 filings availableAccela Pharmaceuticals Private Limited reported revenue of ₹10 Lakh (down 31% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue fell 31% in the latest year. EBITDA fell 32% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹10 Lakh | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹9.75 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹7.74 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 97.5% | ||||
| Net Profit Margin | 77.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Accela Pharmaceuticals Private Limited, buy the company report.
Board of directors of Accela Pharmaceuticals Private Limited
Accela Pharmaceuticals has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pragati Dinesh Bothara Also directs: Indo-Bio Active Labs Private Limited | Director | 30 Mar 2022 | 4 Years 6 Months | Current |
| Dinesh Keshari Chand Bothra | Director | 05 Jul 2010 | 16 Years 3 Months | Current |
Auditor
Accela Pharmaceuticals Private Limited is audited by SMC & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SMC & Associates | FY 2023 | 140208W |
Shareholding
The shareholding of Accela Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Accela Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Accela Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Accela Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Accela Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Accela Pharmaceuticals Private Limited has 6 board changes on record since 2010: 2 appointments and 4 cessations. The latest: Pragati Dinesh Bothara ceased to be Additional Director on 30 Sep 2022.
Frequently asked questions
Accela Pharmaceuticals is an active private limited company based in Pune, Maharashtra, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 05 July 2010 (16+ years old) and is registered under CIN U24232PN2010PTC136759.
Accela Pharmaceuticals has 2 current directors:
- Pragati Dinesh Bothara - Director
- Dinesh Keshari Chand Bothra - Director
The latest financial statements of Accela Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Accela Pharmaceuticals is U24232PN2010PTC136759. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Accela Pharmaceuticals was incorporated on 05 July 2010, making it 16+ years old. It is registered with the Registrar of Companies, Pune.
Pragati Dinesh Bothara ceased to be Additional Director on 30 Sep 2022. Viraj Dhirubhai Shah ceased to be Director on 19 Apr 2022. Pragati Dinesh Bothara was appointed as Director on 30 Mar 2022. Accela Pharmaceuticals has 6 board changes on record in total.
The registered office of Accela Pharmaceuticals is at S No. 118 To 124 Plot No 98 National Soc Aundh, Pune, Maharashtra, India – 411021.
Accela Pharmaceuticals operates in the pharma industry, in the pharma contract r and d segment.
The compliance status of Accela Pharmaceuticals is compliant as of 19 August 2026. The company is actively filing with the Registrar of Companies.
Accela Pharmaceuticals can be reached at its registered office: S No. 118 To 124 Plot No 98 National Soc Aundh, Pune, Maharashtra, India – 411021.